Recently, Cancer Research Institute CEO and Director of Scientific Affairs Jill O’Donnell-Tormey, Ph.D., appeared in two informative Facebook Live broadcasts to discuss current developments and challenges in cancer immunotherapy.
Last week, during the Second International Cancer Immunotherapy Conference (CICON16), O’Donnell-Tormey moderated a Q&A panel with renowned cancer immunology experts Elizabeth Jaffee, M.D., of Johns Hopkins Medicine and Philip Greenberg, M.D., of Fred Hutchinson Cancer Research Center.
Earlier this week, O’Donnell-Tormey sat down with Business Insider’s pharmaceutical and biotech reporter Lydia Ramsey to share the latest advancements in cancer immunotherapy, and highlight CRI’s role in pioneering and leading this vital new field of cancer treatment.
We are grateful for the continued opportunities to provide updates on cancer immunotherapy’s progress and promising future.
CICON16: The Future of Cancer Immunotherapy
Read Previous Article
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
July is Sarcoma Awareness Month. As a rare and difficult-to-treat form of cancer, effective drug treatments are urgently needed and immunotherapy for sarcoma shows promise.
Dr. Joan Levy, director of research at the Chordoma Foundation, discusses the current state of chordoma research and the recently launched partnership with CRI.